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Background: The biological effects of transthyretin proteins on vasculature remain unknown.
Results: V30M transthyretin tetramer modulates endothelial global gene expression, down-regulating pro-angiogenic genes,
inducing apoptosis and inhibiting migration.
Conclusion: Transthyretin proteins regulate angiogenesis by conferring different molecular identities to endothelial cells.
Significance: This work has critical implications in the prevention of early hepatic artery thrombosis in familial amyloidotic
polyneuropathy patients after liver transplantation.
Familial amyloidotic polyneuropathy (FAP) has a high preva-
lence in Portugal, and the most common form of hereditary
amyloidosis is caused by an amyloidogenic variant of transthy-
retin (TTR) with a substitution of methionine for valine at posi-
tion 30 (V30M). Until now, the available efficient therapy is liver
transplantation, when performed in an early phase of the onset
of the disease symptoms. However, transplanted FAP patients
have a significantly higher incidence of early hepatic artery
thrombosis compared with non-FAP transplanted patients.
Because FAP was described as an independent risk factor for
early hepatic artery thrombosis, more studies to understand the
underlying mechanisms involved in this outcome are of the
utmost importance. Knowing that the liver is the major site for
TTR production, we investigated the biological effects of TTR
proteins in the vasculature andonangiogenesis. In this study,we
identified genes differentially expressed in endothelial cells
exposed to theWT or V30M tetramer.We found that endothe-
lial cells may acquire different molecular identities when
exposed to these proteins, and consequentlyTTRcould regulate
angiogenesis. Moreover, we show that V30M decreases endo-
thelial survival by inducing apoptosis, and it inhibits migration.
These findings provide new knowledge that may have critical
implications in the prevention of early hepatic artery thrombo-
sis in FAP patients after liver transplantation.
Familial amyloidotic polyneuropathy (FAP)3 is an inherited
autosomal dominant disease that affects primarily the periph-
eral and autonomic nervous systems. It was first described by
Corino de Andrade, in 1952, in the Northern area of Portugal
(1), and then many foci of FAP cases were reported worldwide
(2–6). FAP is caused by the extracellular deposition of amyloid
fibrils composed of transthyretin (TTR) protein. TTR is a
homotetramic plasma protein of approximately 55 kDa pro-
duced mainly in the liver and choroid plexus of the brain. The
known physiological functions of TTR are the transport of thy-
roid hormone T4 and retinol, through binding to the retinol-
binding protein. To date, approximately 112 mutations in the
primary structure of TTR have been discovered of which 98 are
amyloidogenic. Among the amyloidogenic variants the substi-
tution of Val for Met at position 30 (V30M) is the most com-
monmutation (7, 8). Several studies suggest that amyloidogenic
mutations destabilize the native structure of TTR, thereby
inducing conformational changes that lead to dissociation of
the tetramers into partially unfolded species which can subse-
quently self-assemble into amyloid fibrils (9). The proposed
mechanism under certain physiological conditions, including
temperature, pH, ionic strength, and protein concentration,
states that mutant TTR molecules can dissociate into non-na-
tivemonomers with a distinct compact structure, which in turn
can partially unfold forming high molecular mass soluble
aggregates (10, 11). Quintas et al. have also demonstrated that
there is a clear correlation between the stability of the non-
native monomer formed upon tetramer dissociation, aggregate
formation, and the amyloidogenic potential of different TTR
variants (12). Growing evidence has pointed toward a model
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mechanism of amyloidosis cytotoxicity where amyloidogenic
mutations in TTR destabilize the native structure into dimers
and monomers that rapidly form oligomers and protofibrillar
species which are the cytotoxic intermediates (9, 13, 14).
Although several approaches are being developed to induce
the clearance of extracellular deposition of TTR (for review, see
Ref. 15), so far orthotopic liver transplantation (OLT) has been
the treatment of choice for FAP because this organ is the main
source of TTR production. Because the liver of FAP patients is
usually fully functional, although it produces mutant TTR, in
1995 a new transplant technique, sequential transplantation, or
domino liver transplantation, was developed in Portugal, by a
team led by Prof. Linhares Furtado (16). In the domino trans-
plantation FAP patients receive an organ, while the organ of
the FAP patient is reused for transplantation into another
patient with chronic liver disease. A recent prospective mon-
itoring these transplanted FAP patients has shown prolon-
gation of life, and among the different TTR mutations, the
most favorable results were obtained for patients with the
V30M TTR mutation (17).
Curry Cabral Hospital is presently the most important
liver transplantation center in Portugal. Since the first OLT
performed in this center in 1992, there have been marked
improvements in surgical technique, anesthesia management,
immunosuppressive regimen, and medical care of these patients.
However, early postoperative thrombotic complications, particu-
larly hepatic artery thrombosis (HAT), remain critical causes of
in-hospitalmorbidity, potentially culminating in acute graft loss
(18, 19). A retrospective analysis of 223 OLTs showed that the
incidence of early HAT in FAP patients was 7.7-fold higher
compared with non-FAP patients. The cause for this higher
incidence of HAT could not be justified based on the technical
factors analyzed; preoperative details, surgical features, and
postoperative variables were similar for patients with or with-
out HAT (20). FAP is therefore an independent risk for early
HAT, and it is therefore vital to clarifywhat are themechanisms
involved in this outcome.
Because the liver is themajor site of TTRproduction, wemay
hypothesize that the hepaticmicroenvironment and liver endo-
thelial cells (ECs) respond differentially to the WT or V30M
TTR proteins. To date there is no knowledge on the effects of
these proteins in EC biology.
In the present study, we used DNAmicroarray technology to
investigate the endothelial global gene expression patterns in
response to tetrameric WT and V30M TTR. We report that
genes involved in IFN andTNFpathways are significantlymod-
ulated by V30M TTR compared with the WT and may have a
role in angiogenesis regulation. Accordingly, V30M induces
the down-regulation of several pro-angiogenic genes such as
VEGFR1, VEGFR2, FGF2, TGFB2, and ANGPT2. Moreover,
our results suggest that V30M decreases EC survival by
inducing apoptosis and it inhibits migration. These new
insights into the regulation of endothelial function by these
proteins may have critical implications in the prevention of
early hepatic artery thrombosis in FAP patients after liver
transplantation.
EXPERIMENTAL PROCEDURES
Cell Culture—Primary human umbilical vein endothelial
cells (HUVECs) were kindly provided by Dr. Shahin Rafii (Cor-
nell University Medical College, New York). ECs, passage 6–8,
were cultured as described (21).
Transthyretin Expression and Purification—Recombinant
WT and V30M TTR were produced in an Escherichia coli
expression system and purified as described previously (22), with
minor alterations. WT TTR expression plasmid (pmmHA) was
provided by Jeffery Kelly, and V30M TTR expression plasmid
(pETM-13) was a courtesy of EMBL-GS (Munich, Germany).
E. coli BL21 transformed with the appropriate plasmid was
grownovernight in15-ml starter cultures (LBbrothwith50g/ml
ampicillin, for WT-TTR, or 50 g/ml kanamycin, for V30M-
TTR) at 37 °C and 200 rpm. One-liter cultures (LB broth with
antibiotic) were inoculated with 10 ml of starter cultures and
incubated at 37 °C and 200 rpm until A600 nm  0.4–0.6. Pro-
tein expression was then induced by adding 0.1 mM isopropyl
1-thio--D-galactopyranoside. The purification procedure was
applied both for WT and V30M TTR. After 3 h of protein
expression cells were centrifuged in a Centrifuge 5810R
(Eppendorf) at 9000 rpm for 3 min, at 4 °C, which was followed
by resuspension in TBS, pH 7.6, sonication in a Soniprep 150
(MSE), and centrifugation at 14,000  g for 5 min, at 4 °C.
Because TTR is a soluble protein, cell extracts were then pre-
cipitated with (NH4)2SO4 (40% saturation) followed by centrif-
ugation at 12,000 g for 15 min, at 4 °C. The supernatant was
then brought to 90% (NH4)2SO4 saturation, and precipitated
proteins were harvested by centrifugation in the same condi-
tions as the previous one. The pellets were resuspended in ionic
exchange buffer A (25 mM Tris-HCl, 1 mM EDTA, pH 8) and
dialyzed against the same buffer overnight at 4 °C in dialysis
tubing cellulose membrane (average flat width, 76 mm) from
Sigma-Aldrich. Dialyzed proteins were separated by ionic
exchange chromatography with a Resource Q (GE Healthcare)
after equilibration with 95% buffer A and 5% buffer B (25 mM
Tris-HCl, 1 mM EDTA, 1 M NaCl, pH 8). TTR variants were
collected during a 5–35% buffer B gradient and loaded onto a
HiLoad 16/600 Superdex 75 pg (GEHealthcare) equilibrated in
PBS. Finally, a tetrameric form of both TTRvariants was iso-
lated by gel filtration chromatography as described previously
(12), with an analytical Superdex 200 10/300 GL previously
equilibrated in Hanks’ balanced salt solution.
Transthyretin Quantification and Analysis of the Species in
Solution—Protein concentrations were obtained spectropho-
tometrically at 280 nm using an extinction coefficient of 7.76
104 M1 cm1 based on a molecular mass of 55 kDa for TTR
(A280 nm (1%)  14.1 mg1 ml cm1) (11, 12). To assure that
just the presence of the WT and V30M TTR tetramer were in
the solution, 100l of the final purified TTRwas injected on an
analytical tricorn Superdex 75 (GE Healthcare). Only the sam-
ples with just the TTR tetramer were applied to cells.
RNA Isolation, Target Synthesis, and Hybridization to Affymetrix
GeneChips—Total RNA was extracted from HUVECs and cul-
tured for 3 h in the presence of the purified WT and V30M TTR
proteins at 4 M, using RNeasy Micro Kit (Qiagen). Three dif-
ferent RNA isolates were used as replicates, and total RNA was
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extracted using the RNeasy Mini Kit (Qiagen). Concentration
and purity were determined by spectrophotometry, and integ-
rity was confirmed using an Agilent 2100 Bioanalyzer with a
RNA 6000 Nano Assay (Agilent Technologies, Palo Alto, CA).
RNA was processed for use on Affymetrix GeneChip Human
Gene 1.1 ST Array Strips (NuGEN Technologies, San Carlos,
CA)Ovation PicoSLWTASystemV2, and Encore BiotinMod-
ule, according to the manufacturer’s protocol. Briefly, 17 ng of
total RNAwas used in a reverse transcription reaction to obtain
first-strand cDNA. After generation and purification of DNA-
RNA heteroduplex double-strand cDNA, this was subjected to
SPIA amplification. Size distribution of purified SPIA cDNA
was assessed using an Agilent 2100 Bioanalyzer with a RNA
6000 Nano Assay, followed by fragmentation and end-labeling
of 2.5 g of SPIA cDNA (Encore Biotin Module, NuGEN) and
confirmation using a RNA 6000 Nano Assay. The end-labeled,
fragmented cDNA was used in a 130-l hybridization mixture
containing added hybridization controls (GeneAtlas Hybrid-
ization, Wash, and Stain Kit for WT Array Strips; Affymetrix)
and hybridized on array strips for 20 h at 48 °C. Standard post-
hybridization wash and double-stain protocols (GeneAtlas
Hybridization, Wash, and Stain Kit for WT Array Strips) were
used on an Affymetrix GeneAtlas system, followed by scanning
of the array strips. Microarray data were deposited in the Gene
Expression Omnibus (GEO) repository at the NCBI under
accession number GSE44856.
GeneChipDataAnalysis—Scanned arrayswere analyzed first
with Affymetrix Expression Console software for quality con-
trol. Subsequent analysis was carried out with Chipster 2.3.0
(23). Robust multi-array average was used to compute expres-
sion values for the six arrays in this study and based on custom
cdf file included in hugene11stv1hsentrezg.db as available from
Brainarray database (24). Next 33% of all genes with the lowest
S.D. from the genemean were filtered out, leaving 13,224 genes
of the original 19,738 genes for further analysis. These were
subjected to an empirical Bayes two-group test (25) with Ben-
jamini-Hochberg multiple testing correction and a p value
cut-off of 0.05, resulting in a list of 436 differentially
expressed genes. Ingenuity Pathway Analysis (IPA) (Ingenu-
ity Systems) was used to determine the biological pathways
in which the genes that were significantly over- or underex-
pressed were involved. Our list of significant changed genes,
with respective -fold change and p values was uploaded
within the IPA database and a core analysis was carried out.
Canonical pathways analysis identified the pathways from
the IPA library that were most significantly associated with
the data set. Genes from the data set that met the p value
cut-off of 5% and were associated with a canonical pathway
in the Ingenuity Pathways Knowledge Base were considered
for the analysis.
Apoptosis Analysis—HUVECs were plated at equal densities,
and after 24, 48, 72, 84, or 96 h of incubation with WT and
V30M TTR proteins at different concentrations (1, 2, 4, 8, or
10 M), cells were stained with Annexin V-FITC (Boehringer
Mannheim) and propidium iodide (PI) (Interchim). The percent-
age of apoptotic cells (Annexin V-positive, PI-negative and -posi-
tive)was determinedby flowcytometry (FACSCalibur; BDBiosci-
ences) and Flowjo 6.4.7 software. Results are shown as the
percentage of early and late apoptotic cells (Annexin V-positive/
PI-negative and Annexin V-positive/PI-positive, respectively).
Wound Healing Assay—HUVECs were plated to confluence
andwounds created in themonolayer by scraping the plate with a
pipette tip, after the addition ofWT andV30MTTR proteins at 4
M.Woundedmonolayers were photographed immediately after
wounding and 7 h later, and the area of the woundwasmeasured.
Several regions (n 3) for each treatment done in triplicate were
recorded, and themeans S.D. of each treatmentwere calculated
after normalizing for wounded area at t 0 and expressed as per-
centage of wound healing.
Quantitative RT-PCR (qRT-PCR)—Total RNA from HUVECs
cultured in the presence ofWT and V30MTTR proteins at 4 M
for 5 or 8 hwas isolated using the RNeasyMicro Kit (Qiagen). For
each sample, 1 g of RNA was reverse transcribed into cDNA
(Superscript II Kit; Invitrogen). ThemRNA levels of the following
targets: IFITM1 forward, 5-TCATCCTGTCACTGGTATTC-
GGCTC-3 and reverse, 5-GTGGGTATAAACTGCTGTAT-
CTAGGG-3; BAK1 forward, 5-GGGTCTATGTTCCCCAG-
GAT-3 and reverse, 5-GCAGGGGTAGAGTTGAGCA-3;
TNF forward, 5-GAGCTGTGGGGAGAACAAAAGGA-
3 and reverse, 5-TTGGCCCTTGAAGAGGACCTG-3;
TNFAIP3(A20) forward, 5-CTTGTGGCGCTGAAAACGA-
A-3 and reverse, 5-CCACTGTCCTTCAGGGTCAC-3; FOS
forward, 5-CTCAATGACCCTGAGCCCA-3 and reverse, 5-
TTGCTAATGTTCTTGACCGGC-3; VEGFR1 forward, 5-
CCCTCGCCGGAAGTTGTAT-3 and reverse, 5-GTCAAA-
TAGCGAGCAGATTTCTCA-3; VEGFR2 forward, 5-ATT-
CCTCCCCCGCATCA-3 and reverse, 5-GCTCGTTGGCG-
CACTCTT-3 FGF2 forward, 5-AAGAGCGACCCTCACAT-
CAAGCTA-3 and reverse, 5-TAGCCAGGTAACGGTTAG-
CACACA-3; TGFB2 forward, 5-GCTTTGGATGCGGCCT-
ATTGCTTT-3 and reverse, 5-CTCCAGCACAGAAGTTG-
GCATTGT-3; ANGPT2 forward, 5-AGGACACACCACGA-
ATGGCATCTA-3 and reverse, 5-TGAATAATTGTCCAC-
CCGCCTCCT-3; TUB forward, 5-CATTGGCAATAGCAC-
AGCCATCCA-3 and reverse, 5-ACGAGGTCGTTCATGT-
TGCTCTCA-3; and 18S forward, 5-GCCCTATCAACTTT-
CGATGGTAGT-3 and reverse, 5-CCGGAATCGAACCC-
TGATT-3weremeasuredbyqRT-PCRperformed according to
the manufacturer’s protocol using Power SYBR Green (Invit-
rogen) and an Applied Biosystems 7500 Fast Real-time PCR.
The housekeeping gene used to normalize was 18S. The real-
time PCR program consisted of an initial denaturation step at
95 °C for 10 min followed by 40 cycles at 95 °C for 15 s and at
60 °C for 1 min. The relative quantification was performed ac-
cording to the comparative method (2-Ct; Applied Biosys-
tems User Bulletin 2P/N 4303859), with WT condition as
internal calibrator and 18S as normalizer. The Ct value for
each sample is representative of three different experiments.
RESULTS
Differential Response of ECs to V30M TTR Compared with
WT TTR: Human Microarray Study—To characterize the EC
response to WT and V30M TTR, we employed DNA microar-
ray analysis, which is a powerful tool for analyzing global
changes in gene expression. HUVECs were incubated withWT
andV30MTTR tetramers at the final concentration of 4M for
Transthyretin Proteins Regulate Angiogenesis
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3 h. We chose this concentration because it is the one that
resembles the plasma levels of TTR 25 mg/dl (17, 26).
Changes in mRNA expression are given as -fold changes com-
paring V30M TTR versus WT TTR-treated cells. All changes
are significant with Benjamini-Hochberg-adjusted p values
	0.05. In our study, 213 genes with a ratio of 1.42 or above and
223 genes with a ratio of 1.42 or below were considered up-
regulated or down-regulated by V30M, respectively. A list of
the top 10 up- or down-regulated genes is presented in Table 1.
Of notice are the most down-regulated genes of the data set,
c-fos and fosB, with a -fold change of3.76 and3.67, respec-
tively, both belonging to the fos gene family. To further investi-
gate the biological relevance of the data obtained from the gene
expression microarrays, we used IPA software. The genes con-
sidered to have been differentially regulatedwere uploaded into
IPA along with the gene identifiers and corresponding -fold
change values. IPA constructs networks that optimize for both
interconnectivity and number of focus genes under the con-
straint ofmaximal network size. In the graphical representation
of a network, genes or gene products are represented as nodes,
and the biological relationship between two nodes is repre-
sented as an edge (line). The intensity of the node color indi-
cates the degree of up (red) or down (green) regulation of a
given gene. Nodes are displayed using various shapes that rep-
resent the functional class of the gene product. Edges are dis-
played with various labels that describe the nature of the rela-
tionship between the nodes. By this analysis, we explored the
molecular interactions and biological processes in which the
genes significantly modified by V30M TTR could be involved.
Canonical pathways analysis identified molecular pathways
that were most significant to the data set. The top 10 canonical
signaling pathways are illustrated in Fig. 1. IFN and TNF are
two of themost relevant canonical pathways. In the IFN signal-
ing pathway, the transcript encoding for the T cell protein-
tyrosine phosphatase, described as being involved in silencing
of VEGFR2 signaling and inhibiting biological responses to
VEGF (27), is up-regulated in ECs exposed to V30MTTRwhen
compared with the WT TTR. In contrast, the IFN-induced
transmembrane protein 1 (IFITM1), described as regulator of
EC sprouting in vitro and angiogenesis in vivo (28), and the
pro-apoptotic Bak1 protein are down-regulated in ECs exposed
to V30M TTR. In TNF signaling pathway, the transcripts
encoding for the cytokine TNF and for the zing finger protein
A20 are up-regulated in V30M exposed ECs. TNF is described
as a potent inducer of EC apoptosis (29, 30) whereas A20 has
been well established as a dual inhibitor of nuclear factor-B
(NF-B) activation and apoptosis in the TNF receptor 1 signal-
ing pathway. Moreover, in this signaling pathway, the tran-
script encoding for the proto-oncogene c-fos is down-regu-
lated in ECs exposed to V30M. c-fos dimerizes withmembers
of Jun family to form AP-1, a transcription factor involved in
the regulation of VEGF, one of the most important angio-
genic factors (31).
qRT-PCR of Microarray Data—Although microarrays are a
powerful tool to study global transcriptional responses, it is
important to confirm microarray data. With this objective,
HUVECs were cultured in the presence of TTR tetrameric pro-
teins, at 4 M, for 5 or 8 h, and total RNA was extracted. Quan-
titative RT-PCR validated decreased IFITM1 and c-fos expres-
sion and increased A20 and TNF expression by the V30M TTR
tetramer. We found that BAK1 expression, one of the top 10
down-regulated genes in the arrays analysis at 3 h, is marginally
down-regulated at 5 h but significantly increased at 8 h (Fig. 2)
TABLE 1
Top 10 most up-regulated and down-regulated genes induced by
V30M TTR compared with WT TTR
ADNAmicroarray analysis was used to characterize the endothelial cell response to
WT and V30M tetrameric TTR proteins. HUVECs were incubated with WT and
V30MTTR tetramers at the final concentration of 4M for a period of 3 h. Changes
inmRNA expression are given as -fold changes comparing V30MTTR-treated cells
versusWTTTR-treated cells. All changes are significantwith Benjamini-Hochberg-
adjusted p values	0.05.
Gene symbol Gene description
-Fold
change
Up-regulated
SNORD59B Small nucleolar RNA, C/D box 59B 2.73
POM121L9P POM121 membrane glycoprotein-like 9,
pseudogene
2.35
SNORD49A Small nucleolar RNA, C/D box 49A 2.18
SNORD113-4 Small nucleolar RNA, C/D box 113-4 2.06
SNORD114-3 Small nucleolar RNA, C/D box 114-3 2.06
SNORD14C Small nucleolar RNA, C/D box 14C 2.05
HSD17B7 Hydroxysteroid (17) dehydrogenase 7 2.02
CLK4 CDC-like kinase 4 2.01
MIR186 MicroRNA 186 2.00
SNORD114-2 Small nucleolar RNA, C/D box 114-2 1.95
Down-regulated
ANAPC1 Anaphase-promoting complex subunit 1 2.01
BAK1 BCL2-antagonist/killer 1 2.04
FAM103A1 Family with sequence similarity 103,
member A1
2.05
OR10G9 Olfactory receptor, family 10, subfamily
G, member 9
2,07
LOC100286979 Similar to anaphase-promoting complex
subunit 1
2.09
EGR1 Early growth response 1 2.16
HIST1H2BK Histone cluster 1, H2bk 2.20
CDC20 Cell division cycle 20 homolog
(Saccharomyces cerevisiae)
2.20
FOSB FBJ murine osteosarcoma viral
oncogene homolog B
3.67
FOS FBJ murine osteosarcoma viral
oncogene homolog
3.76
FIGURE 1. IPA software was used to analyze the differentially regulated
genes. IPA showing canonical pathways was significantly modulated by
V30MTTR comparedwithWT.Only the 10pathwayswith themost significant
changes are shown. The p value for each pathway is indicated by the bar and
is expressed as negative log of Benjamini-Hochberg-adjusted p value; thresh-
old is at 1.25  log (p  0.05). The gray squares represent the ratio of the
number of genes in a given pathway that meet the cut-off criteria divided by
the total number of genes that make up that pathway.
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in ECs exposed to V30M TTR compared with cells exposed to
the WT TTR tetramer.
V30M TTR Tetramers Down-regulate Pro-angiogenic Gene
Expression in HUVECs—Because our experimental data sug-
gest that angiogenesis may be modulated by V30M TTR, we
investigated the levels of expression of other proteins known to
be important in angiogenesis such as VEGFR1, VEGFR2, FGF2,
TGFB2, and ANGPT2. According to our microarray data the
expression of these targets does not change at 3 h by the V30M
TTR tetramer. For that reason, the expression of these selected
pro-angiogenic molecules was assessed later. Therefore,
HUVECs were cultured in the presence of the WT and V30M
TTR tetramer, at 4 M, for 5 or 8 h followed by RNA extraction
and quantitative RT-PCR analysis. Our results suggest that
V30M induces a down-regulation of all selected genes (Fig. 3).
Moreover, the expression of tubulin, here used as a putative
unchanged target by theWTandV30MTTR tetramer, remains
identical (Fig. 3A).
V30M TTR Decreases EC Survival by Inducing Apoptosis—
According to our findings, the V30M TTR tetramer regulates
genes involved in one of the most important pro-angiogenic
pathway, VEGF/VEGFR2, described as being fundamental in
endothelial survival. For that reason,we assessed the capacity of
V30M to induce apoptosis. HUVECs were incubated with WT
and V30M TTR tetrameric proteins, at different concentra-
tions, for 24, 48, and 72 h, and then ECs were labeled with
Annexin V-FITC and PI. As shown in Fig. 4 A, there is an
increase of the percentage of apoptosis in a concentration-de-
pendent manner when HUVECs were cultured with the V30M
compared with HUVECs cultured with theWT TTR tetramer.
The values obtained for the WT TTR tetramer do not change
with the different concentrations or over time (Fig. 4A) and are
similar to those observed when HUVECs are cultured in nor-
malmedium in the absence of any type of TTRprotein (data not
shown).
Because 4 M is the dose that resembles the plasma levels of
TTR25 mg/dl (17, 26), we investigated whether the percent-
age of EC apoptosis that was obtained with this dose (Fig. 4A, 4
M) could be augmented if the time of incubation increased.
HUVECs were incubated with WT or V30M TTR tetrameric
proteins at 4M for 24, 48, 72, 84, and 96h, and as observed (Fig.
4B) V30MTTR tetramer significantly increases the percentage
of apoptosis over time in contrast to the WT. Moreover, an
additional experimental condition was added (Fig. 4B) where
HUVECs were cultured in the presence of bothWT and V30M
TTR tetrameric proteins (at 2 M, each). The same procedure
was performed as described above, and according to our results
FIGURE 2. Validation of selected microarray targets by qRT-PCR. HUVECs
were incubated for 5 h (A) or 8 h (B) with WT and V30M TTR tetrameric pro-
teins. Relative expression of selected targets from the IFN pathway (IFITM1
and BAK1) and from TNFR2 pathway (TNF, TNFAIP3, c-fos) were quantified by
qRT-PCR.Data represent the -fold change ingeneexpressionof each target in
V30M TTR-treated cells relative to the internal calibrator (WT TTR-treated
cells) in triplicate measurements. Chart values are representative of three
independent experiments.
FIGURE 3. V30M TTR tetramers modulate the expression of several pro-
angiogenic targets inHUVECs.Cellswere incubated for 5h (A) or 8h (B)with
WT and V30M TTR tetrameric proteins. Relative expression of selected pro-
angiogenic genes (VEGFR1, VEGFR2, ANGPT2, FGF2, and TGFB2) and cytoskel-
eton-relatedprotein tubulin (TUB) was quantifiedbyqRT-PCR.Data represent
the -fold change in gene expression of each target in V30M TTR-treated cells
relative to the internal calibrator (WT TTR-treated cells) in triplicate measure-
ments. Chart values are representative of three independent experiments.
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the percentage of apoptosis after 48 h is significantly superior
when ECs are cultured simultaneously in the presence of both
types of proteins (WT and V30M) compared with the values
obtained when ECs are cultured exclusively in the presence of
WT, but significantly inferior compared with those obtained
when ECs are cultured exclusively in the presence of V30M.
Furthermore, we investigated whether the percentage of EC
apoptosis that was obtained in this particular condition could
be changed by the addition of fresh tetramer every 24 h over
96 h. Accordingly, HUVECs were incubated withWT or V30M
TTR tetrameric proteins at 4 M or both proteins (at 2 M) for
24, 48, 72, 84, and 96 h. Every 24 h, the medium was removed,
and fresh medium was added with the respective tetramers.
ECswere labeledwithAnnexinV-FITC andPI and the percent-
age of apoptosis analyzed at indicated times (Fig. 4C). As
observed in Fig. 4C, the results were similar to those obtained
when tetramers were added uniquely at the beginning of the
experiment (Fig. 4B).
V30MTTR Tetramer Inhibits ECMigration—We also inves-
tigated the effect of the V30M TTR tetramer in EC migration
because our results suggest that TTR may regulate angiogene-
sis, and we know that in this process cell migration is essential.
Confluent HUVECmonolayers were exposed to either protein,
at 4 M, and an in vitro wound healing assay was performed.
The EC migratory response to wounding was measured. As
represented in Fig. 5, ECs in the presence of the WT achieved
almost 85%wound closure after 7 h, whereas V30MTTR inhib-
ited closure by approximately 1.4-fold (60%wound closure). At
7 h after wounding, neither type of TTR protein induces apo-
ptosis (data not shown), suggesting that the result obtained is
independent of a putative effect of V30M in EC survival.
DISCUSSION
Orthotopic liver transplant for FAP has become the usual
treatment of choice for this fatal disease. However, trans-
planted FAP patients have a significantly higher incidence of
early hepatic artery thrombosis comparedwith non-FAP trans-
planted patients. Because FAPwas described as an independent
risk factor for early HAT, more studies aiming to clarify this
phenomenon are needed to develop specific prevention strate-
gies for this population. Knowing that the livers of FAP patients
are anatomically and functionally normal except for the pro-
duction of the mutant TTR, we hypothesized that ECs may
acquire different molecular identities when exposed to WT or
mutant TTR proteins, and consequently TTR could regulate
angiogenesis. To the best of our knowledge, the biological
effects of TTR proteins in the vasculature and on angiogenesis
were unknown.
To address this issue, we investigated global gene expression
of HUVECs cultured in the presence of the WT and V30M
FIGURE 4. V30M TTR decreases endothelial cell survival by inducing apoptosis. A, HUVECs were cultured in the presence of WT and V30M TTR tetrameric
proteins at 1, 2, 4, 8, or 10M for 24, 48, and72h.After thementioned incubationperiods cellswere stainedwithAnnexinV-FITCandPI.B, HUVECswere cultured
(i) in the presence of 4MWT TTR; (ii) in the presence of 4MV30MTTR; (iii) in the presence of 2MWT and 2MV30MTTR for 24, 48, 72, 84, and 96 h. After the
mentioned incubation periods cells were stained with Annexin V-FITC and PI. C, HUVECs were cultured (i) in the presence of 4 M WT TTR; (ii) in the presence
of 4M V30M TTR; (iii) in the presence of 2MWT and 2M V30M TTR for 24, 48, 72, 84, and 96 h. Every 24 h, themediumwas removed, and freshmediumwas
added with the respective tetramers. After the incubation periods cells were stained with Annexin V-FITC and PI. A–C, values are given as the percentage of
apoptotic cells (Annexin V-positive, PI-negative and -positive) in culture. Data are shown as mean S.D. of triplicate cultures and are representative of three
independent experiments. A, *, p	 0.0005; B and C, *, p	 0.00025.
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tetrameric TTRproteins, at 4M, a concentration similar to the
one found physiologically. The first key finding of this work is
the identification of differentially expressed genes in ECs
exposed to the WT or V30M TTR tetramer. By microarray
analysis, we found that the expression of a total of 436 genes
differed significantly between the ECs exposed to the WT and
V30M tetramer. To identify mechanisms behind experimental
observations of changes in gene expression, our data sets were
analyzed through the use of IPA canonical pathways. The IFN
and TNF signaling pathways were identified as canonical path-
ways that weremost significant to the data set. Interestingly, all
of the mediators observed to be up- or down-regulated in these
particular pathways, namely T cell protein-tyrosine phospha-
tase, IFITM1, BAK1, TNF,A20, and c-fos, are involved in endo-
thelial cell survival and angiogenesis regulation, the second key
finding of this work. To validate our microarray data set, qRT-
PCR was performed. Consistently, the V30M TTR tetramer
induces a down-regulation of the transcript levels of IFITM1
and c-fos and an up-regulation of TNF andA20, in HUVECs, at
5 or 8 h of exposure. IFITM1 and c-fos are both involved in
angiogenesis regulation. IFITM1 was found to be rapidly
induced as EC sprout in vitro and form luminized vessels. Using
a vascular bed xenotransplant model, a role for the human
IFITM1was identified during in vivo angiogenesis (28). IFITM1
was described as a molecule that may regulate the transition of
ECs from a quiescent to an angiogenic state (28). Because we
found that V30M tetrameric protein induces a decrease in
IFTM1 expression, this could be related to an anti-angiogenic
response that could be in agreement with our results that sug-
gest that V30M inhibits EC migration. The protein c-fos het-
erodimerizes with Jun proteins to form the transcription factor
AP-1. According to our microarray analysis, Jun expression is
not significantly changed by V30M, a finding that was con-
firmed by qRT-PCR (data not shown). Taken together, our
results suggest that the expression of AP-1 may be conse-
quently decreased in HUVECs exposed to V30M. One of the
genes regulated by AP-1 is one of the most important angio-
genic factors, VEGF (31). Moreover, it was also described that,
in ECs, AP-1 is also involved in the transcription of interleukin
8 (IL-8), which acts in an autocrine fashion to suppress apopto-
sis and facilitate cell proliferation and migration (32). In agree-
ment with our results that suggest that V30M induces AP-1
down-regulation, our observations shown that V30M induces
apoptosis and inhibits EC migration, the third key finding of
our work.
The proteins TNF and A20 are mainly involved in the regu-
lation of EC survival. TNF, up-regulated by V30M TTR
tetramer, is a potent inducer of EC apoptosis, consistent with
the effect of V30M in inducing EC apoptosis. Concerning A20,
it is difficult to predict its biological effect in ECs exposed to
V30M, where we found that its expression levels are up-regu-
lated, because this protein has a dual role. Although A20 inhib-
its apoptosis mediated by the TNF signaling, it paradoxically
inhibits NF-B. In most cell types, it has been well established
that activation of NF-B antagonizes apoptotic cell death trig-
gered by TNF signaling. Moreover, our results suggest that
BAK1, one of the 10 top down-regulated genes byV30MTTR in
our array analysis (performed at 3 h), is marginally down-regu-
lated at 5 h. This suggests that even though the levels of BAK1
significantly decrease at 3 h of V30M TTR exposure, this slight
effect is seen later, at 5 h, and interestingly, at 8 h, the levels of
expression of BAK1 transcripts are significantly increased by
V30M TTR compared with the WT tetramer. BAK1 is a pro-
apoptotic gene, and its up-regulation by V30M TTR is consist-
ent with our results showing that V30M induces HUVECs to
undergo apoptosis. According to our findings for BAK1, we
hypothesized that other molecular targets playing a role in
angiogenesis and that do not appear as significantly altered in
our microarray data set (performed at 3 h) could be differen-
tially expressed by V30MTTR tetramer later on. Therefore, we
selected several genes such as VEGFR1, VEGFR2, FGF2,
TGFB2, and ANGPT2. The receptors 1 and 2 of VEGF
(VEGFR1 and VEGFR2) are the main mediators of VEGF-in-
duced endothelial proliferation, survival, migration, tubular
morphogenesis, and sprouting in adults (33, 34). Moreover, it
has been long recognized that FGF2, TGFB2, and ANGP2 are
important in angiogenesis inducingmigration andproliferation
of ECs, stimulating tube formation and sprouting of new blood
vessels (35). Here, we found that HUVECs present a down-
regulation of the expression of all of these angiogenic players
after 5 or 8 h of exposure to V30M comparedwith theWTTTR
tetramer. Therefore, our results consistently raise the possibil-
ity that TTR proteins differentially regulate endothelial gene
expression, conferring different molecular identities to ECs.
Accordingly, V30M TTR tetramer decreases the expression
levels of several genes involved in endothelial proliferation, sur-
vival, and migration and could negatively modulate angiogen-
FIGURE 5. V30M TTR tetramer inhibits endothelial cell migration. A,
HUVECs were cultured until confluent, and the monolayer was scraped to
initiate wounding immediately after the addition of TTR tetrameric proteins
at 4 M. Monolayers were followed over time and the wound area was mea-
sured at t0h and t7h.Magnification,10.B, quantitationof results from
several regions (n3) for each treatmentdone in triplicatewas recorded, and
the means  S.D. of each treatment were calculated after normalizing for
wounded area at t 0 and expressed as percentage of wound healing. *, p	
0.0002.
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esis compared with the WT TTR tetramer. Our results pro-
vide the important insight that TTR protein plays a key
regulatory role in angiogenesis whereby themutant V30M or
WT tetramer differentially activates ECs, inducing a specific
pattern of gene expression. According to the cellular path-
ways and molecular targets that are expressed, distinct vas-
cular responses will be dictated by the V30M or theWT TTR
tetramer.
To the best of our knowledge, the evidence that FAP patients
could develop diseases associated with angiogenesis deficiency
has not been previously noted. We can hypothesize that the
normal life span of the FAP patientminimizes the chance of the
development of angiogenesis-related diseases. However, FAP
was recently identified as an independent risk factor for early
thrombotic complications and specifically for HAT following
OLToften culminating in acute graft loss (20). The cause of this
phenomenon is not known. In light of presented data, we can
hypothesize that the sudden change in serum levels of TTR
V30M to WT can be challenging to FAP donor ECs. Knowing
that FAP is an autosomal dominant disease, it is expectable that
in the majority of FAP patients, their ECs could be exposed
simultaneously to theWT and V30M proteins, but even so, our
results suggest that ECs are biologically affected by V30M
because an induction of apoptosis is observed in the presence of
both tetrameric proteins. However, according to our results
suggesting that the percentage of apoptosis is significantly dif-
ferent among ECs exposed to both types of TTR tetrameric
proteins and ECs exposed exclusively to V30M tetrameric pro-
tein, we expect that ECs from homozygotic or heterozygotic
FAP patients for V30M may respond differentially. Neverthe-
less, homozygotic or heterozygotic FAP patients for V30M
were exposed to TTR V30M through life, which induced a low
angiogenic potential. Few hours after OLT, the microenviron-
ment is altered, and the vasculature should respond to a WT
protein (produced by the new transplanted liver), which
induces different biological pathways and gene expression
favoring angiogenesis and ECproliferation. Also, as reported by
our surgeons, HAT occurs mainly in the donor side of vascular
anastomosis (data not shown). This fact is in accordance with
our description. However, HAT is not a concern of FAP
patients only, occurring also in non-FAP receptors. Thismeans
that local factors must be taken into account. Nonetheless, an
existing vascular anastomosis is a huge stress factor for angio-
genesis. It may partially explain why the thrombosis events
occur in the anastomosis area, not at distant sites. This study
highlighted the severe problem of high incidence HAT in FAP
recipients during OLT. We consider that with this work new
knowledge has been introduced in this area, but the problem
remains. Further investigation is needed to clarify this matter,
mainly which interventional treatments are required.
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